SLC25A35

Summary

SLC25A35 (solute carrier family 25 member 35, HGNC:31921) is a protein-coding gene on chromosome 17p13.1, encoding Solute carrier family 25 member 35 (Q3KQZ1). Putative antiporter that exchanges dicarboxylates and sulfur oxoanions across the inner membrane of mitochondria.

SLC25A35 belongs to the SLC25 family of mitochondrial carrier proteins (Haitina et al., 2006 [PubMed 16949250]).

Source: NCBI Gene 399512 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 61 total — 1 pathogenic
• MANE Select transcript: NM_001320870

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31921
Approved symbol	SLC25A35
Name	solute carrier family 25 member 35
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ40217
Ensembl gene	ENSG00000125434
Ensembl biotype	protein_coding
OMIM	610818
Entrez	399512

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000380067, ENST00000577745, ENST00000579192, ENST00000579681, ENST00000580340, ENST00000581320, ENST00000585311, ENST00000879454, ENST00000939395, ENST00000939396, ENST00000939397

RefSeq mRNA: 5 — MANE Select: NM_001320870 NM_001320870, NM_001320871, NM_001320872, NM_001320877, NM_201520

CCDS: CCDS11138, CCDS82067

Canonical transcript exons

ENST00000577745 — 5 exons

Exon	Start	End
ENSE00000949096	8290842	8290976
ENSE00001118092	8291333	8291485
ENSE00001118095	8292523	8292588
ENSE00002686402	8294433	8295400
ENSE00002720733	8290061	8290678

Expression profiles

Bgee: expression breadth ubiquitous, 186 present calls, max score 89.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.6271 / max 89.7745, expressed in 1733 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164427	6.9760	1676
164426	0.6511	409

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	89.81	gold quality
left testis	UBERON:0004533	89.07	gold quality
right testis	UBERON:0004534	89.03	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.93	gold quality
left ventricle myocardium	UBERON:0006566	88.17	gold quality
epithelial cell of pancreas	CL:0000083	86.51	gold quality
testis	UBERON:0000473	86.31	gold quality
pancreatic ductal cell	CL:0002079	85.24	silver quality
metanephros cortex	UBERON:0010533	84.61	gold quality
right uterine tube	UBERON:0001302	84.52	gold quality
mucosa of transverse colon	UBERON:0004991	84.41	gold quality
body of stomach	UBERON:0001161	82.90	gold quality
granulocyte	CL:0000094	82.34	gold quality
right adrenal gland cortex	UBERON:0035827	81.92	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.63	gold quality
right adrenal gland	UBERON:0001233	81.56	gold quality
metanephros	UBERON:0000081	81.31	gold quality
pituitary gland	UBERON:0000007	81.13	gold quality
adenohypophysis	UBERON:0002196	80.88	gold quality
germinal epithelium of ovary	UBERON:0001304	80.26	gold quality
left adrenal gland	UBERON:0001234	80.01	gold quality
left adrenal gland cortex	UBERON:0035825	79.88	gold quality
right lobe of thyroid gland	UBERON:0001119	79.61	gold quality
apex of heart	UBERON:0002098	79.54	gold quality
adrenal cortex	UBERON:0001235	79.52	gold quality
adult mammalian kidney	UBERON:0000082	79.46	gold quality
nasal cavity epithelium	UBERON:0005384	79.38	gold quality
placenta	UBERON:0001987	79.31	gold quality
superficial temporal artery	UBERON:0001614	79.25	gold quality
cortex of kidney	UBERON:0001225	78.85	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	7.79
E-ANND-3	yes	6.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting SLC25A35, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-891B	99.59	69.81	1083
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-3190-5P	98.87	64.89	1345

Literature-anchored findings (GeneRIF, showing 1)

• Compares and contrasts all the known human SLC25A* genes and includes functional information. (PMID:23266187)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc25a35	ENSDARG00000102783
mus_musculus	Slc25a35	ENSMUSG00000018740
rattus_norvegicus	Slc25a35	ENSRNOG00000004668

Paralogs (49): SLC25A13 (ENSG00000004864), SLC25A5 (ENSG00000005022), SLC25A39 (ENSG00000013306), SLC25A40 (ENSG00000075303), SLC25A3 (ENSG00000075415), SLC25A43 (ENSG00000077713), SLC25A24 (ENSG00000085491), SLC25A1 (ENSG00000100075), SLC25A17 (ENSG00000100372), SLC25A14 (ENSG00000102078), SLC25A15 (ENSG00000102743), SLC25A11 (ENSG00000108528), UCP1 (ENSG00000109424), SLC25A36 (ENSG00000114120), SLC25A12 (ENSG00000115840), SLC25A2 (ENSG00000120329), SLC25A51 (ENSG00000122696), SLC25A16 (ENSG00000122912), SLC25A19 (ENSG00000125454), SLC25A23 (ENSG00000125648), SLC25A47 (ENSG00000140107), SLC25A52 (ENSG00000141437), SLC25A38 (ENSG00000144659), SLC25A26 (ENSG00000144741), SLC25A48 (ENSG00000145832), SLC25A37 (ENSG00000147454), SLC25A25 (ENSG00000148339), SLC25A31 (ENSG00000151475), SLC25A4 (ENSG00000151729), SLC25A27 (ENSG00000153291), SLC25A28 (ENSG00000155287), SLC25A44 (ENSG00000160785), SLC25A45 (ENSG00000162241), SLC25A34 (ENSG00000162461), SLC25A32 (ENSG00000164933), SLC25A6 (ENSG00000169100), SLC25A33 (ENSG00000171612), SLC25A30 (ENSG00000174032), UCP3 (ENSG00000175564), UCP2 (ENSG00000175567)

Protein

Protein identifiers

Solute carrier family 25 member 35 — Q3KQZ1 (reviewed: Q3KQZ1)

All UniProt accessions (1): Q3KQZ1

UniProt curated annotations — full annotation on UniProt →

Function. Putative antiporter that exchanges dicarboxylates and sulfur oxoanions across the inner membrane of mitochondria.

Subcellular location. Mitochondrion inner membrane.

Similarity. Belongs to the mitochondrial carrier (TC 2.A.29) family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q3KQZ1-1	1	yes
Q3KQZ1-2	2
Q3KQZ1-3	3
Q3KQZ1-4	4

RefSeq proteins (5): NP_001307799, NP_001307800, NP_001307801, NP_001307806, NP_958928 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018108	MCP_transmembrane	Repeat
IPR023395	MCP_dom_sf	Homologous_superfamily
IPR051508	Mito_Carrier_Antiporter	Family

Pfam: PF00153

Catalyzed reactions (Rhea), 1 shown:

• a dicarboxylate(in) + sulfate(out) = a dicarboxylate(out) + sulfate(in) (RHEA:76595)

UniProt features (14 total): transmembrane region 6, splice variant 3, repeat 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3KQZ1-F1	87.99	0.41

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 116 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, AP4_Q6, CEBPB_01, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, MCBRYAN_PUBERTAL_BREAST_3_4WK_UP, HNF4_DR1_Q3, GOCC_MITOCHONDRIAL_ENVELOPE, TGACATY_UNKNOWN, OCT1_B, CP2_01, GOCC_ORGANELLE_INNER_MEMBRANE, SMAD4_Q6, GOCC_ORGANELLE_ENVELOPE, OCT_Q6, LIM_MAMMARY_STEM_CELL_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

352 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC25A35	SLC25A53	Q5H9E4	614
SLC25A35	SLC25A39	Q9BZJ4	571
SLC25A35	SLC25A51	Q9H1U9	531
SLC25A35	SLC25A41	Q8N5S1	498
SLC25A35	SLC38A8	A6NNN8	456
SLC25A35	CPSF4L	A6NMK7	451
SLC25A35	SLC25A52	Q3SY17	432
SLC25A35	TRIL	Q7L0X0	430
SLC25A35	SVOPL	Q8N434	415
SLC25A35	SDF2	Q99470	413
SLC25A35	SLC7A3	Q8WY07	407
SLC25A35	JHY	Q6NUN7	375
SLC25A35	SLC15A5	A6NIM6	374
SLC25A35	SLC25A37	Q9NYZ2	369
SLC25A35	SLC25A22	Q9H936	366

IntAct

14 interactions, top by confidence:

A	B	Type	Score
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
LPAR4	POTEF	psi-mi:“MI:0914”(association)	0.530
SLC25A35	CPT2	psi-mi:“MI:0915”(physical association)	0.400
SLC12A6	SLC25A35	psi-mi:“MI:0915”(physical association)	0.400
SLC25A36	SLC25A35	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
MGARP	RTL8C	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
AQP3	RTL8C	psi-mi:“MI:0914”(association)	0.350
GCGR	GPR89A	psi-mi:“MI:0914”(association)	0.350
FECH	GTPBP10	psi-mi:“MI:0914”(association)	0.350
SLC2A2	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): SEC23B (Affinity Capture-MS), PMVK (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), PMVK (Affinity Capture-MS), DDAH2 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), TRAPPC2 (Two-hybrid), TRAPPC2B (Two-hybrid), SLC25A35 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), CPT2 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS), SLC25A35 (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2K309, A0A1D6N272, A3KPP4, G3XP90, G3YD89, O13844, P04575, P04633, P12234, P12242, P16036, P33303, Q08DK7, Q0VCH6, Q1LZB3, Q27257, Q29RM1, Q3KQZ1, Q3TZX3, Q505J6, Q58DS3, Q5HZE0, Q5IS35, Q5NVC1, Q5R7W2, Q5SWT3, Q6AYL0, Q6DFK2, Q6P036, Q6P316, Q7K566, Q8BGP6, Q8BL03, Q8BZ09, Q8N8R3, Q8TBP6, Q8VEM8, Q93XM7, Q99JD3, Q9BSK2

Diamond homologs: A0A0G2K5L2, A2ADF7, A4QNX2, B0G143, F1LX07, F1LZW6, F1RFX9, O13844, O43772, O75746, P16261, P39953, Q02978, Q08DK4, Q0II44, Q12482, Q1DRJ3, Q21153, Q26365, Q3KQZ1, Q3TZX3, Q4V8K4, Q505J6, Q54QN2, Q54RB9, Q552L9, Q58DS3, Q5B717, Q5RBC8, Q5RD81, Q5SWT3, Q5XIF9, Q5ZKP7, Q66L49, Q68F18, Q6ZT89, Q75AH6, Q7PQV7, Q86AV5, Q8BH59

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	45
Likely benign	10
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2422139	NC_000017.10:g.(?7123304)(8193254_?)del	Pathogenic

SpliceAI

1137 predictions. Top by Δscore:

Variant	Effect	Δscore
17:8290835:T:TA	donor_gain	1.0000
17:8290838:TTA:T	donor_loss	1.0000
17:8290839:TACCT:T	donor_loss	1.0000
17:8290840:A:AC	donor_gain	1.0000
17:8290841:C:CA	donor_loss	1.0000
17:8290841:C:CC	donor_gain	1.0000
17:8290841:CCTTG:C	donor_gain	1.0000
17:8290972:AAGAT:A	acceptor_gain	1.0000
17:8290973:AGAT:A	acceptor_gain	1.0000
17:8290974:GAT:G	acceptor_gain	1.0000
17:8290975:AT:A	acceptor_gain	1.0000
17:8290977:C:CC	acceptor_gain	1.0000
17:8290691:C:CT	acceptor_gain	0.9900
17:8290692:A:T	acceptor_gain	0.9900
17:8290840:AC:A	donor_gain	0.9900
17:8290841:CC:C	donor_gain	0.9900
17:8290841:CCTT:C	donor_gain	0.9900
17:8290985:G:C	acceptor_gain	0.9900
17:8291485:CCTAG:C	acceptor_gain	0.9900
17:8294427:TCTTA:T	donor_loss	0.9900
17:8294428:CTTA:C	donor_loss	0.9900
17:8294429:TTA:T	donor_loss	0.9900
17:8294430:TACCA:T	donor_loss	0.9900
17:8294431:A:AC	donor_gain	0.9900
17:8294431:A:C	donor_loss	0.9900
17:8294432:C:CC	donor_gain	0.9900
17:8288675:C:G	donor_gain	0.9800
17:8288861:GTAAG:G	donor_loss	0.9800
17:8288862:TAAGG:T	donor_loss	0.9800
17:8288863:AAGGT:A	donor_loss	0.9800

AlphaMissense

1936 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:8291366:G:C	F187L	0.997
17:8291366:G:T	F187L	0.997
17:8291368:A:G	F187L	0.997
17:8294445:G:C	S121R	0.997
17:8294445:G:T	S121R	0.997
17:8294447:T:G	S121R	0.997
17:8290603:C:G	G269R	0.996
17:8290926:A:C	S215R	0.996
17:8290926:A:T	S215R	0.996
17:8290928:T:G	S215R	0.996
17:8292583:C:A	K127N	0.996
17:8292583:C:G	K127N	0.996
17:8294615:C:G	G65R	0.996
17:8294731:C:A	R26M	0.996
17:8294736:C:A	K24N	0.996
17:8294736:C:G	K24N	0.996
17:8290891:T:A	D227V	0.995
17:8294754:A:C	N18K	0.995
17:8294754:A:T	N18K	0.995
17:8292575:A:G	L130P	0.994
17:8294730:C:A	R26S	0.994
17:8294730:C:G	R26S	0.994
17:8294731:C:G	R26T	0.994
17:8290876:C:A	R232M	0.993
17:8290876:C:G	R232T	0.993
17:8290891:T:G	D227A	0.993
17:8294462:C:G	G116R	0.993
17:8294462:C:T	G116R	0.993
17:8294722:A:G	L29S	0.993
17:8290875:C:A	R232S	0.992

dbSNP variants (sampled 300 via entrez): RS1000293054 (17:8288471 C>A,T), RS1000900275 (17:8297114 T>C), RS1001212839 (17:8294232 A>T), RS1001662128 (17:8294061 G>A,C), RS1001767233 (17:8295934 T>A,G), RS1002302847 (17:8291016 C>T), RS1002397567 (17:8290771 A>G), RS1002449567 (17:8292097 A>G), RS1002656850 (17:8295071 G>A), RS1002666869 (17:8295393 C>G,T), RS1003532491 (17:8288728 A>T), RS1003557719 (17:8295688 T>G), RS1004152798 (17:8288092 C>T), RS1004275175 (17:8293698 C>A), RS1004309337 (17:8294057 A>C)

Disease associations

OMIM: gene MIM:610818 | disease phenotypes: MIM:201475

GenCC curated gene-disease

Mondo (2): cardiac rhythm disease (MONDO:0007263), very long chain acyl-CoA dehydrogenase deficiency (MONDO:0008723)

Orphanet (1): Very long chain acyl-CoA dehydrogenase deficiency (Orphanet:26793)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Mitochondrial di- and tri-carboxylic acid transporter subfamily

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation, increases expression	3
Nickel	decreases expression	2
Tretinoin	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
potassium perchlorate	decreases expression	1
beta-lapachone	decreases expression	1
arsenite	decreases methylation	1
sodium arsenite	affects expression	1
abrine	decreases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Diethylhexyl Phthalate	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	increases expression	1
Lactic Acid	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4VG	LS180-SLC25A35-KO-c2	Cancer cell line	Female
CVCL_D4VH	LS180-SLC25A35-KO-c3	Cancer cell line	Female
CVCL_TM36	HAP1 SLC25A35 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

265 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00146822	PHASE4	COMPLETED	REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance
NCT00187239	PHASE4	COMPLETED	Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study
NCT00247533	PHASE4	UNKNOWN	Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
NCT00282620	PHASE4	UNKNOWN	Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient’s Quality of Life.
NCT00290056	PHASE4	UNKNOWN	Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial
NCT00313443	PHASE4	COMPLETED	Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
NCT00457340	PHASE4	COMPLETED	Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00507390	PHASE4	WITHDRAWN	Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia
NCT00575523	PHASE4	COMPLETED	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
NCT00579098	PHASE4	COMPLETED	The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation
NCT01613092	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01628666	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01717469	PHASE4	UNKNOWN	Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
NCT01819064	PHASE4	COMPLETED	Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
NCT01834872	PHASE4	UNKNOWN	Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation
NCT01841242	PHASE4	COMPLETED	Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation
NCT01991223	PHASE4	UNKNOWN	Dexmedetomidine for Catheter-related Bladder Discomfort
NCT02045173	PHASE4	COMPLETED	Automate Detection of Sleep Apnea by ApneascanTM
NCT02203630	PHASE4	TERMINATED	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
NCT02565069	PHASE4	COMPLETED	Identification for the Treatment of Complex Arrhythmias
NCT03273634	PHASE4	COMPLETED	The Effect of Proton Pump Inhibition on Palpitations
NCT03289429	PHASE4	UNKNOWN	Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery
NCT03895411	PHASE4	UNKNOWN	Efficacy and Safety of Sotalol in Children With Arrhythmia
NCT05486377	PHASE4	COMPLETED	Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
NCT06574555	PHASE4	COMPLETED	Norepinephrine ED90 Bolus After Spinal Anesthesia in Cesarean Section
NCT00000464	PHASE3	COMPLETED	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
NCT00000476	PHASE3	COMPLETED	Digitalis Investigation Group (DIG)
NCT00000480	PHASE3	COMPLETED	Multicenter Unsustained Tachycardia Trial (MUSTT)
NCT00000492	PHASE3	COMPLETED	Beta-Blocker Heart Attack Trial (BHAT)
NCT00000502	PHASE3	COMPLETED	Evaluation of SC-V Versus Conventional CPR
NCT00000517	PHASE3	COMPLETED	Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
NCT00000518	PHASE3	COMPLETED	Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
NCT00000531	PHASE3	COMPLETED	Antiarrhythmics Versus Implantable Defibrillators (AVID)
NCT00000540	PHASE3	COMPLETED	Coronary Artery Bypass Graft (CABG) Patch Trial
NCT00000556	PHASE3	COMPLETED	Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
NCT00000561	PHASE3	COMPLETED	Mode Selection Trial in Sinus Node Dysfunction (MOST)
NCT00000609	PHASE3	COMPLETED	Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
NCT00004559	PHASE3	COMPLETED	Fatty Acid Antiarrhythmia Trial (FAAT)
NCT00004560	PHASE3	COMPLETED	Public Access Defibrillation (PAD) Community Trial
NCT00035490	PHASE3	COMPLETED	Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators